---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-24-000084"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:53:43.142572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q1 net loss narrows to $8.1M; net revenue nil after adjustments

## Summary
- Net revenue nil after periodic review of accounting estimates for older tests; gross revenue $39K vs $100K YoY.
- Net loss $8.1M, improved 24% from $10.6M loss in Q1 2023.
- Operating expenses $9.1M, down 20% YoY; SG&A $5.4M (-26%), R&D $3.7M (-10%).
- Shipped first ambient whole blood collection kits to reduce COGS and expand access.
- Submitted PRIME study interim analysis manuscript for peer-reviewed publication.

## SEC filing metadata
- accession: 0001534969-24-000084
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496924000084/0001534969-24-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496924000084/sera-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-24-000084
- JSON: https://secwatch.observer/filing/0001534969-24-000084.json
- Plain text: https://secwatch.observer/filing/0001534969-24-000084.txt

## Key facts
- Earnings Releases
  SERA PROGNOSTICS, INC. reported first quarter ended March 31, 2024 results: revenue nil, net income $8.1 million loss.
  - Period: first quarter ended March 31, 2024
  - Revenue: nil
  - Net income: $8.1 million loss
  - Result: reported results
  source text: First quarter 2024 revenue before adjustments was $39,000 compared to $100,000 for the same period of 2023, but net revenue was nil after our periodic review of accounting estimates for older tests.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534969/000153496924000084/0001534969-24-000084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.